Splenectomy for non-haematological metastatic XXXX .

@entity1 @entity43 @entity66 @entity5 @entity3 @entity320
PURPOSE: Multiple cases and small series of @entity1 who have undergone splenectomy for metastatic @entity5 have been reported. This study examines the outcome of @entity1 with metastatic @entity5 to the spleen treated by splenectomy at a tertiary oncology centre and a review of cases published in the last 10  years. METHODS: The hospital histopathology database was searched over a 25-year period up to 2004 for @entity1 who had undergone splenectomy for non-haematological @entity5 . Medical records of these @entity1 were reviewed and clinical course was examined. The literature review was undertaken using a search of PubMed for the terms "splenectomy" and " @entity3 " from 2000 to 2010. RESULTS: Twenty-one cases at our institution were identified. The most common primary site of @entity5 was ovary (nine cases), followed by @entity320 (three) and pancreas (three). There were two cases of @entity3 from colonic primary and one each from renal, breast, nasopharyngeal and unknown @entity66 . There were two cases of long-term disease-free survival (both primary @entity43 ) and four cases of @entity1 who survived more than 4  years but had disease recurrence (ovarian and colonic primaries). The literature review provided a further 115 cases. CONCLUSIONS: More favorable outcomes were seen in @entity1 with @entity66 . There was a trend to improved outcome in ovarian and colorectal primaries over @entity320 . It is postulated that improved outcome may be seen in @entity1 for whom there were effective adjuvant chemotherapeutic options, low probability of other @entity3 and @entity5 biology. However, frequently the presentation is indicative of aggressive @entity66 with a poor prognosis.
